Amgen acquires Roche rights to Neupogen and Neulasta
Amgen announced that it has entered into a definitive agreement with F. Hoffmann-La Roche to acquire Roche's rights to filgrastim (Neupogen) and pegfilgrastim (Neulasta) in approximately 100 markets, effective Jan. 1, 2014 .Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, Inc. (a joint venture between Amgen and Kirin Holdings Co. Limited , of Japan ) in Eastern Europe , Latin America , Asia , the Middle East and Africa since 1989. The franchise generated approximately $200 million in sales in these territories in 2012.
Filgrastim and pegfilgrastim are white blood cell boosting therapeutics used to reduce the risk of infection in patients receiving chemotherapy. They are marketed by Amgen in he United States and Europe under the trade names NEUPOGEN® and Neulasta, respectively.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins